Results 251 to 260 of about 647,962 (308)
Some of the next articles are maybe not open access.
Clinics in Liver Disease, 2003
Hepatotoxicity is the most common cause of fulminant hepatic failure in the United States and the main indication for market withdrawal of drugs. This condition has been increasingly recognized as a problem of enormous medical, financial legal, and regulatory importance.
Timothy J, Davern, Nathan M, Bass
openaire +2 more sources
Hepatotoxicity is the most common cause of fulminant hepatic failure in the United States and the main indication for market withdrawal of drugs. This condition has been increasingly recognized as a problem of enormous medical, financial legal, and regulatory importance.
Timothy J, Davern, Nathan M, Bass
openaire +2 more sources
Progress in Cardiovascular Diseases, 2004
Calcium antagonists were introduced for the treatment of hypertension in the 1980s. Their use was subsequently expanded to additional disorders, such as angina pectoris, paroxysmal supraventricular tachycardias, hypertrophic cardiomyopathy, Raynaud phenomenon, pulmonary hypertension, diffuse esophageal spasms, and migraine.
Ehud, Grossman, Franz H, Messerli
openaire +2 more sources
Calcium antagonists were introduced for the treatment of hypertension in the 1980s. Their use was subsequently expanded to additional disorders, such as angina pectoris, paroxysmal supraventricular tachycardias, hypertrophic cardiomyopathy, Raynaud phenomenon, pulmonary hypertension, diffuse esophageal spasms, and migraine.
Ehud, Grossman, Franz H, Messerli
openaire +2 more sources
The Lancet, 1999
The very potent endogenous vasoconstrictor endothelin was discovered in 1988. We know now that there are three isoforms (1, 2, and 3) and two receptor subtypes (A and B). A whole range of peptide and non-peptide antagonists has been developed, some selective for A or B receptors and others with non-selective A/B antagonistic activity.
A, Benigni, G, Remuzzi
openaire +2 more sources
The very potent endogenous vasoconstrictor endothelin was discovered in 1988. We know now that there are three isoforms (1, 2, and 3) and two receptor subtypes (A and B). A whole range of peptide and non-peptide antagonists has been developed, some selective for A or B receptors and others with non-selective A/B antagonistic activity.
A, Benigni, G, Remuzzi
openaire +2 more sources
1966
Publisher Summary Vitamin K activity is shared by a fairly large number of compounds. They consist, in the main, of two naturally occurring groups of compounds: phylloquinones (K), containing saturated isoprenoid side chains, and menaquinones (MK) with unsaturated isoprenoid side chains.
openaire +3 more sources
Publisher Summary Vitamin K activity is shared by a fairly large number of compounds. They consist, in the main, of two naturally occurring groups of compounds: phylloquinones (K), containing saturated isoprenoid side chains, and menaquinones (MK) with unsaturated isoprenoid side chains.
openaire +3 more sources
Molecular Diversity, 2008
CCR1 (CC Chemokine receptor 1) is a widely studied G protein-coupled receptor target expressed on multiple types of leukocytes. It is implicated in initiating and exacerbating inflammatory conditions and thus is viewed as a good target for autoimmune and inflammatory therapeutic applications. Numerous CCR1 antagonists have been reported.
Jie-Fei, Cheng, Rick, Jack
openaire +2 more sources
CCR1 (CC Chemokine receptor 1) is a widely studied G protein-coupled receptor target expressed on multiple types of leukocytes. It is implicated in initiating and exacerbating inflammatory conditions and thus is viewed as a good target for autoimmune and inflammatory therapeutic applications. Numerous CCR1 antagonists have been reported.
Jie-Fei, Cheng, Rick, Jack
openaire +2 more sources
Antagonists to the benzodiazepines
British Dental Journal, 1984P, McGonigal, C N, Schofield
openaire +3 more sources
BMS-813160: A Potent CCR2 and CCR5 Dual Antagonist Selected as a Clinical Candidate
ACS Medicinal Chemistry Letters, 2021Percy Carter +2 more
exaly
Temporary Remissions in Acute Leukemia in Children Produced by Folic Acid Antagonist...Aminopterin
Ca-A Cancer Journal for Clinicians, 1974S Farber
exaly